

# **EFFICACY OF TRIPLE THERAPY WITH PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS IN CLINICAL PRACTICE**

P. Selvi-Sabater<sup>1</sup>, I. Gorostiza-Frias<sup>1</sup>, I. Sanchez-Martinez<sup>1</sup>, A.M. Rizo-Cerdá<sup>1</sup>, N. Manresa-Ramón<sup>1</sup>, T. Alonso-Dominguez<sup>1</sup>, M. Soria-Soto<sup>1</sup>, B. Arrisas-Diaz<sup>1</sup>, J.C. Titos-Arcos<sup>1</sup>, M.A. Arias-Moya<sup>2</sup>

<sup>1</sup>Hospital Morales Meseguer. Murcia

<sup>2</sup>Fundación Jiménez Díaz, Pharmacy, Madrid, Spain

## **Background:**

Given the large number of new drugs for the treatment of hepatitis C virus (HCV) and the high economic cost, it is important to decide which treatment is best suited to each patient.


## **Purpose:**

To evaluate the efficacy of triple therapy with protease inhibitors for the treatment of HCV in clinical practice.

## **Material and methods:**

Two-year retrospective study including all patients treated with triple therapy for HCV. Analyzed parameters were: sex, age, HCV genotype, liver fibrosis, type of patient (pretreated / naive) HIV co-infection and HCV viral load (VL). The collected data were obtained by reviewing medical records, and Savac® prescription and validation program

**Results:** 26 patients Median age: 52 years



Genotype: 1a 11 (42%) 1b 15 (58%)

The most common liver fibrosis was grade 3

After finishing the treatment, 23 patients had undetectable viral load (one of the patients presented detectable viral load at week 4 and two of them at week 12). Twenty-four weeks after the treatment, 22 of them had sustained viral response (SVR). In the table we can see the response rates based on the drug and/or patient characteristics

	Nº of patients	Week 4	Week 12	Week 24	Week 48	SVR
<b>Total</b>	26	96,15%	92,31%	92,31%	88,46%	<b>84,62%</b>
<b>Telaprevir</b>	19	94,74%	89,47%	89,47%	89,47%	<b>84,21%</b>
<b>Boceprevir</b>	7	100%	100%	100%	85,71%	<b>85,71%</b>
<b>Naive</b>	10	100%	100%	100%	90%	<b>90%</b>
<b>Previously-treated</b>	16	93,75%	87,50%	87,50%	87,50%	<b>81,25%</b>
<b>Relapsers</b>	8	100%	100%	100%	100%	<b>100%</b>
<b>Partial response</b>	7	87,50%	75,00%	75,00%	75,00%	<b>62,50%</b>
<b>Null responders</b>	1	100%	100%	100%	100%	<b>100%</b>

## **Conclusion:**

The triple therapy treatment is a highly effective treatment that gets a SVR in most patients.